Mesenchymal stromal cells: Current understanding and clinical status

Stem Cells

Volumn 28, Issue 3, 2010, Pages 585-596

  Salem, Husein K ^a   Thiemermann, Chris ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dentritic cells; Kidney; Mesenchymal stromal cells; Myocardium; Stem cells; T lymphocytes

Indexed keywords

CISPLATIN;

ACUTE KIDNEY FAILURE; CELL MIGRATION; CELL THERAPY; CELLULAR DISTRIBUTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CROHN DISEASE; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKEMIA; LIVER CIRRHOSIS; LIVER FAILURE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OSTEOGENESIS IMPERFECTA; REVIEW; STROMA CELL; TIBIA FRACTURE;

ANIMALS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; LEUKOCYTES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; STROMAL CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77950551326     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.269     Document Type: Review

References (127)

1. Rossant J. Stem cells from the mammalian blastocyst. Stem Cells 2001;19:477-482.
2. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872. (Pubitemid 350138099)
3. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008;100:133-158. (Pubitemid 351932182)
4. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000;28:875-884.
5. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000;105:1663-1668.
6. Friedenstein AJ et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-247.
7. Tokcaer-Keskin Z, Akar AR, Ayaloglu-Butun F et al. Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: A perspective for emergencies. Can J Physiol Pharmacol 2009;87:143-150.
8. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147. (Pubitemid 29282067)
9. Jori FP, Napolitano MA, Melone MA et al. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem 2005;94:645-655. (Pubitemid 41420266)
10. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: Isolation, in vitro expansion and characterization. Handb Exp Pharmacol 2006:249-282.
11. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74. (Pubitemid 27161245)
12. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006;5:91-116.
13. Jiang X, Cui P, Chen W et al. [Study on the directed inducing process of cartilage cells differentiated from human marrow mesenchymal stem cells]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2002;37:137-139.
14. Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-395. (Pubitemid 41671625)
15. Bühring HJ, Battula VL, Treml S et al. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007;1106:262-271. (Pubitemid 47443036)
16. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213. (Pubitemid 43960310)
17. Peister A, Mellad JA, Larson BL et al. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-1668. (Pubitemid 38268957)
18. Bensidhoum M, Chapel A, Francois S et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 2004;103:3313-3319. (Pubitemid 38525658)
19. Pereira RF, Halford KW, O'Hara MD et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 1995;92:4857-4861.
20. Rochefort GY, Delorme B, Lopez A et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006;24:2202-2208. (Pubitemid 44527473)
21. Wynn RF, Hart CA, Corradi-Perini C et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643-2645. (Pubitemid 39434942)
22. He Q, Wan C, Li G. Concise review: Multipotent mesenchymal stromal cells in blood. Stem Cells 2007;25:69-77. (Pubitemid 46052976)
23. Chapel A, Bertho JM, Bensidhoum M et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028-1038. (Pubitemid 40310427)
24. Breitbach M, Bostani T, Roell W et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007;110:1362-1369. (Pubitemid 47281438)
25. Ley K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-689. (Pubitemid 47327397)
26. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004;4:432-444. (Pubitemid 38745555)
27. Luster, AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005;6:1182-1190. (Pubitemid 43045626)
28. Spring H, Schüler T, Arnold B et al. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A 2005;102:18111- 18116. (Pubitemid 41798510)
29. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005;106:1901-1910.
30. Honczarenko M, Le Y, Swierkowski M et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030-1041. (Pubitemid 44464736)
31. Ringe J, Strassburg S, Neumann K et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 And CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007;101:135-146. (Pubitemid 46652579)
32. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999;181:67-73. (Pubitemid 29400373)
33. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003;10:228-241. (Pubitemid 36302404)
34. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419-427. (Pubitemid 40981232)
35. Lapidot, T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci 2001;938:83-95.
36. Abbott JD, Huang Y, Liu D et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004;110:3300-3305. (Pubitemid 39557491)
37. Bhakta S, Hong P, Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. Cardiovasc Revasc Med 2006;7:19-24. (Pubitemid 43305207)
38. Li N, Lu X, Zhao X et al. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Stem Cells 2009;27:961-970.
39. Ponomaryov T, Peled A, Petit I et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000;106:1331-1339.
40. Sasaki M, Abe R, Fujita Y et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008;180:2581-2587.
41. Inokuma D, Abe R, Fujita Y et al. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem Cells 2006;24:2810-2816. (Pubitemid 46053018)
42. Ip JE, Wu Y, Huang J et al. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007;18:2873-2882. (Pubitemid 47235295)
43. Kershaw DB, Thomas PE, Wharram BL et al. Molecular cloning, expression, and characterization of podocalyxin-like protein 1 from rabbit as a transmembrane protein of glomerular podocytes and vascular endothelium. J Biol Chem 1995;270:29439-29446.
44. Lee RH, Seo MJ, Pulin AA et al. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009;113:816-826.
45. Kemp KC, Hows J, Donaldson C. Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma 2005;46:1531-1544. (Pubitemid 41700985)
46. Son BR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-1264. (Pubitemid 44464694)
47. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ et al. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res 2007;27:53-64. (Pubitemid 46185062)
48. Li Y, Yu X, Lin S et al. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem Biophys Res Commun 2007;356:780-784. (Pubitemid 46499034)
49. Potapova IA, Gaudette GR, Brink PR et al. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 2007;25:1761-1768.
50. Kansas, GS. Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259-3287.
51. Schweitzer KM, Dräger AM, van der Valk P et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996;148:165-175. (Pubitemid 26019654)
52. Lowe, JB. Glycosyltransferases and glycan structures contributing to the adhesive activities of L-, E- and P-selectin counter-receptors. Biochem Soc Symp 2002;33-45.
53. Peled A, Kollet O, Ponomaryov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, And VLA-5 On Immature Human CD34(+) cells: Role In transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95:3289-3296.
54. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-3944. (Pubitemid 44864580)
55. De Becker A, Van Hummelen P, Bakkus M et al., Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 2007;92:440-449. (Pubitemid 350144289)
56. Ries C, Egea V, Karow M et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood 2007;109:4055-4063.
57. Steingen C, Brenig F, Baumgartner L et al. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 2008;44:1072-1084.
58. Rubio D, Garcia S, Paz MF et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 2008;3:e1398. (Pubitemid 351194017)
59. Rubio D, Garcia-Castro J, Martín MC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035-3039. (Pubitemid 40524580)
60. Miura M, Miura Y, Padilla-Nash HM et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006;24:1095-1103. (Pubitemid 44464742)
61. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389-397.
62. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20. (Pubitemid 38019084)
63. Götherström C, Ringdén O, Tammik C et al. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004;190:239-245. (Pubitemid 38156354)
64. Stagg J, Pommey S, Eliopoulos N et al. Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570-2577. (Pubitemid 43348704)
65. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-2749. (Pubitemid 350127858)
66. Frumento G, Rotondo R, Tonetti M et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-468.
67. Munn DH, Shafizadeh E, Attwood JT et al. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372. (Pubitemid 29227522)
68. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today 1999;20:469-473.
69. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621. (Pubitemid 38745993)
70. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-234. (Pubitemid 46053063)
71. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105:4120-4126. (Pubitemid 40656164)
72. Li YP, Paczesny S, Lauret E et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008;180:1598-1608.
73. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004;13:263-271. (Pubitemid 38738368)
74. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822. (Pubitemid 40223708)
75. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells after antigen-presenting cell maturation and induced T-cell unresponsiveness. Blood 2005;105:2214-2219. (Pubitemid 40731815)
76. Rasmusson I, Ringdén O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-2013. (Pubitemid 37339646)
77. Angoulvant D, Clerc A, Benchalal S et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004;41:469-476. (Pubitemid 39277103)
78. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398. (Pubitemid 44464808)
79. Sotiropoulou PA, Perez SA, Gritzapis AD et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006;24:74-85.
80. Gronthos S, Zannettino AC, Hay SJ et al., Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003;116:1827-1835. (Pubitemid 36582169)
81. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482-1490. (Pubitemid 40691430)
82. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005;365:417-430.
83. Szczypka MS, Westover AJ, Clouthier SG et al. Rare incorporation of bone marrow-derived cells into kidney after folic acid-induced injury. Stem Cells 2005;23:44-54.
84. Ito T, Suzuki A, Imai E et al. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001;12:2625-2635. (Pubitemid 33115409)
85. Sáenz-Morales D, Escribese MM, Stamatakis K et al. Requirements for proximal tubule epithelial cell detachment in response to ischemia: Role of oxidative stress. Exp Cell Res 2006;312:3711-3727. (Pubitemid 44637176)
86. Thurman, JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2007;123:7-13.
87. Devarajan, P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006;17:1503-1520. (Pubitemid 43841396)
88. Morigi M, Imberti B, Zoja C et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004;15:1794-1804. (Pubitemid 38822058)
89. Lange C, Tögel F, Ittrich H et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005;68:1613-1617. (Pubitemid 43169906)
90. Tögel F, Hu Z, Weiss K et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-F42. (Pubitemid 40863570)
91. Herrera MB, Bussolati B, Bruno S et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004;14:1035-1041.
92. Crop MJ, Baan CC, Korevaar SS et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009;87:896-906.
93. Held PK, Al-Dhalimy M, Willenbring H et al. In vivo genetic selection of renal proximal tubules. Mol Ther 2006;13:49-58.
94. Kunter U, Rong S, Djuric Z et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:2202-2212. (Pubitemid 44141910)
95. Wood, DA. Preventing clinical heart failure: The rationale and scientific evidence. Heart 2002;88 Suppl 2:ii15-22.
96. Kajstura J, Cheng W, Reiss K et al. Apoptotic and necrotic myocyte cell death are independent contributing variables of infarct size in rats. Lab Invest 1996;74:86-107. (Pubitemid 26041012)
97. Cheng W, Kajstura J, Nitahara JA et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 1996;226:316-327. (Pubitemid 26260556)
98. Zhao ZQ, Morris CD, Budde JM et al. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 2003;59:132-142.
99. Tam SK, Gu W, Mahdavi V et al. Cardiac myocyte terminal differentiation. Potential for cardiac regeneration. Ann N Y Acad Sci 1995;752:72-79.
100. Kajstura J, Leri A, Finato N et al. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad SciU S A 1998;95:8801-8805. (Pubitemid 28350569)
101. Beltrami AP, Urbanek K, Kajstura J et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001;344:1750-1757. (Pubitemid 32497029)
102. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: Mechanisms and management. Am J Cardiol 1991;68:1D-6D.
103. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995;18:1417-1426.
104. Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705. (Pubitemid 29122423)
105. Reyes M, Dudek A, Jahagirdar B et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-346. (Pubitemid 34141807)
106. Bittira B, Kuang JQ, Al-Khaldi A et al. In vitro preprogramming of marrow stromal cells for myocardial regeneration. Ann Thorac Surg 2002;74:1154-1159; discussion 1159-1160.
107. Xu W, Zhang X, Qian H et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004;229:623-631. (Pubitemid 38878907)
108. Shake JG, Gruber PJ, Baumgartner WA et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002;73:1919-1925; discussion, 1926.
109. Nagaya N, Kangawa K, Itoh T et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005;112:1128-1135. (Pubitemid 41216119)
110. Jiang CY, Gui C, He AN et al. Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction. J Zhejiang Univ Sci B 2008;9:630-637.
111. Price MJ, Chou CC, Frantzen M et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol 2006;111:231-239. (Pubitemid 44107562)
112. Wang CC, Chen CH, Lin WW et al. Direct intramyocardial injection of mesenchymal stem cell sheet fragments improves cardiac functions after infarction. Cardiovasc Res 2008;77:515-524.
113. Dohmann HF, Perin EC, Takiya CM et al. Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: Postmortem anatomicopathologic and immunohistochemical findings. Circulation 2005;112:521-526.
114. Perin EC, Silva GV, Assad JA et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 2008;44:486-495.
115. Katritsis DG, Sotiropoulou PA, Karvouni E et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005;65:321-329. (Pubitemid 40898172)
116. Abdel-Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007;167:989-997. (Pubitemid 46835786)
117. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95. (Pubitemid 38813459)
118. Chen SL, Fang WW, Qian J et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004;117:1443-1448. (Pubitemid 39530218)
119. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141-148. (Pubitemid 38891685)
120. Dai W, Hale SL, Martin BJ et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 2005;112:214-223. (Pubitemid 40982304)
121. Noiseux N, Gnecchi M, Lopez-Ilasaca M et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006;14:840-850. (Pubitemid 44752717)
122. Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685. (Pubitemid 38387752)
123. Hung SC, Pochampally RR, Chen SC et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007;25:2363-2370.
124. Macmillan ML, Blazar BR, DeFor TE et al., Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant 2009;43:447-454.
125. Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-1738. (Pubitemid 47086763)
126. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;115:389-398.
127. Gonzalo-Daganzo R, Regidor C, Martín-Donaire T et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009:11:278-288.